HDAC9 and Parkinson disease: Although pharmacological inhibition of HDAC activity is currently under investigation as disease modifying PD therapy [100,109], some of their effects may be mediated by mechanisms unrelated to histone acetylation, such as microtubule stabilization [110,111].